Last updated Nov 3, 2026
A 55-year-old man with peripheral neuropathy and autonomic dysfunction develops heart failure. His father had similar symptoms and died in his 60s. Genetic testing reveals a TTR mutation.
AD; TTR (transthyretin); missense variants with a gain of function: they destabilize the transthyretin tetramer, which comes apart into subunits that form amyloid.
- p.Val142Ile (legacy name Val122Ile) common in African Americans
- p.Val50Met (legacy name Val30Met) common in endemic areas (Portugal, Sweden, Japan)
Transthyretin is made mainly by the liver, and also by the retina and choroid plexus, and circulates as a tetramer of four identical subunits. Pathogenic variants change the shape of the subunit, so a tetramer containing it comes apart more easily. The freed subunits polymerize into amyloid fibrils in tissues. The mechanism is gain of function.
Severity depends on a balance between instability and secretion. The most unstable proteins are degraded before secretion, so their blood levels stay low and they do not cause severe systemic disease. The most severe variant, p.Leu75Pro, is the most unstable one still secreted at normal levels, consistent with disease variants being missense rather than nonsense or deletions. The least stable variants cause central nervous system disease, because the choroid plexus secretes unstable transthyretin more readily than the liver. Most variants cause peripheral and autonomic neuropathy, while p.Val142Ile gives a cardiac-dominant picture with little neuropathy.
Treatment follows the mechanism: tetramer stabilizers such as tafamidis hold the tetramer together, and gene silencers lower production. Neither liver transplant nor these drugs affect choroid plexus production, so central nervous system disease can emerge on therapy.
- Progressive sensorimotor polyneuropathy
- Cardiomyopathy (restrictive/infiltrative)
- Autonomic dysfunction (orthostatic hypotension, GI, erectile dysfunction)
- Vitreous opacities
- Tissue biopsy shows amyloid with Congo red apple-green birefringence under polarized light; mass spectrometry or immunohistochemistry types the deposit to distinguish ATTR from AL amyloidosis
- Technetium pyrophosphate (Tc-99m PYP) cardiac scintigraphy is highly sensitive and specific for ATTR cardiac amyloid and can confirm it noninvasively
- TTR sequencing distinguishes hereditary (variant) ATTR from wild-type, age-related ATTR and enables cascade testing
- Tafamidis (transthyretin tetramer stabilizer; the only drug approved for the cardiomyopathy), TTR gene silencers (second-generation vutrisiran or eplontersen are safer and more effective than patisiran or inotersen), liver transplant (no longer first line; limited indication)
"Trans-thy-retin": The protein name tells you its function: it TRANSports THYroid hormone and RETINol (vitamin A) in the blood. When it misfolds, it forms amyloid deposits in the heart and nerves